

Original Research Article

A novel method to determine new potent angiotensin inhibitor, azilsartan, in human plasma via micelle-enhanced spectrofluorimetry using cremophor RH 40

Hany W Darwish^{1,2*}, Ahmed H Bakheit¹, Ali S Abdelhameed¹ and Bakheit Mustafa³

¹Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457 Riyadh, 11451, Kingdom of Saudi Arabia, ²Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St, Cairo 11562, Egypt, ³El-Neelain University, Faculty of Science and Technology, Department of Chemistry, PO Box 12702, Khartoum, Sudan

*For correspondence: **Email:** hdarwish75@yahoo.com

Received: 17 February 2016

Revised accepted: 9 April 2016

Abstract

Purpose: To develop a micelle-enhanced spectrofluorimetric method for the assay of azilsartan (AZL) in bulk form and spiked human plasma without the need for derivatization procedure.

Method: The proposed method was based on studying the fluorescence behavior of AZL in Cremophor RH 40 (Cr RH 40) micellar system. The fluorescence intensity was measured at 371 nm after excitation at 264 nm. The proposed procedure was validated according to International Council on Harmonization (ICH) guidelines.

Results: In aqueous solution, the fluorescence intensity of AZL was greatly enhanced by more than 3-fold in the presence of Cr RH 40. The fluorescence –concentration plot was linear over the range of 10 – 500 ng.mL⁻¹, with a limit of detection of 3.287 ngmL⁻¹. The proposed method was successfully applied to the determination of AZL in pure powder form and spiked human plasma. The mean recovery of AZL in spiked human plasma using the proposed method was 90.54 ± 1.17 %.

Conclusion: The suggested method is highly sensitive and simple, and can easily be applied for the quantification of AZL in pure powder form as well as in biological fluids such as plasma

Keywords: Azilsartan, Spectrofluorimetry, Spiked human plasma, Micellar system

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Hypertension affects about 74.5 million individuals in the United States [1]. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled, with slightly less than half of patients who receive medication successfully achieving adequate blood pressure (BP) [2]. While there are many drug classes available to reduce BP, drugs that modulate the renin-angiotensin-aldosterone system (RAAS) are more commonly used

because of their efficacy, in addition to their low side effects [3]. Within the RAAS classes, those that inhibit the action of angiotensin II by binding directly to the angiotensin type 1 (AT1) receptor (i.e. angiotensin receptor blockers [ARBs]) are the best tolerated of all antihypertensive drug classes [3].

Azilsartan medoxomil is a new ARB developed for management of hypertension. It is a prodrug that is rapidly hydrolyzed to its active moiety, azilsartan (AZL). Chemically, AZL is known as 2-

Ethoxy-1-{{2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenyl}methyl}-1H-benzimidazole-7-carboxylic acid. The US Food and Drug Administration (FDA) approved Edarbi® tablet (azilsartan medoxomil potassium) on February 25, 2011 to treat hypertension in adults [4]. It is available in 80 mg and 40 mg dosages with the recommended dose of 80 mg daily. Spectrofluorimetric analysis is a very simple, highly sensitive and inexpensive technique that is available at almost all analytical laboratories. The sensitivity of spectrofluorimetry is enhanced by different ways including micellar enhanced approach.

Several micelle-enhanced spectrofluorimetric studies have been reported for the determination of various drugs [5-7]. This fact is due to the ability of the formed micelle to enhance the fluorescence intensity of the weakly fluorescent molecules. Moreover, these procedures represent sensitive and eco-friendly methodology as there is no need for organic solvents. Micellar enhanced analytical methods are relied on addition of surfactants such as sodium dodecyl sulphate (SDS) [7,8], Tween [9,10] and cyclodextrin, etc [11,12]. Nevertheless, using non-ionic surfactant "Cremophor RH 40" is not familiar in the reported methods for determination of drugs. Cremophor RH 40 is manufactured by reacting 40 mol of ethylene oxide with hydrogenated castor oil. It contains mainly the tricrinoleate ester of ethoxylated glycerol, with smaller amounts of polyethylene glycol ricinoleate and the corresponding free glycols [13].

A thorough survey of the literature revealed that few reports were published recently for assaying AZL alone in dosage form using high-performance liquid chromatography (HPLC) [14-16], UV spectrophotometry [17], high-performance thin layer chromatography (HPTLC) [14, 18] and in dog and human plasma using LC/MS [19,20]. AZL in combination with chlorthalidone was also determined in dosage form using UV and fluorescence spectrophotometry [21], HPLC [22-25] and in human and rat plasma using LC/MS [26]. Fluorescence spectrometry is a very simple, rapid, efficient, selective, and highly sensitive technique for determination of drug in plasma [27-29]. Therefore, the aim of the current study is to develop and validate a new sensitive, simple and rapid micelle-enhanced spectrofluorimetric method for the in vitro determination of AZL in spiked human plasma. The current procedure

does not involve derivatization step due to the intrinsic fluorescent property of AZL.

EXPERIMENTAL

Apparatus

Fluorescence measurements were carried out on a fluorescence spectrometer (model FP-8200, Jasco Corporation, Japan) equipped with a 150 W xenon lamp and 1 cm quartz cells. The slit widths for both the excitation and emission monochromators were set at 5.0 nm. The calibration and linearity of the instrument were frequently checked with standard quinine sulphate (0.01 µg/mL). Wavelength calibration was performed by measuring λ_{ex} at 275 nm and λ_{em} at 430 nm; no variation in the wavelength was observed. All recorded spectra converted to ASCII format by SpectraManager® software. A Hanna pH-Meter (Romania) was used for pH adjustments.

Reagents and materials

All the chemicals used were of analytical reagents grade, and the solvents were of HPLC grade. Azilsartan reference standard (purity, ~ 99.6 %) was purchased from Weihua Pharma Co. Ltd (Zhejiang, China). Polyoxyl 40 hydrogenated castor oil (Cremophor RH40), Polyoxyl 35 hydrogenated castor oil (Cremophor EL) were purchased from BASF (Ludwigshafen, Germany) and used as 1 % w/v aqueous solution for Cremophor EL and 1 % v/v aqueous solution for Cremophor EL. Sodium dodecyl sulphate (SDS, 95 %) was purchased from Winlab (UK) and used as 1 % w/v aqueous solution. β -cyclodextrin (β -CD) and carboxymethylcellulose (CMC) were obtained from Merck (Germany) and used as 1 % w/v aqueous solution. Tween-20, tween-80 and tween-85 (Techno Pharmchem Haryana Company (INDIA)), were used as 1 % v/v aqueous solution. Methanol, ethanol (Prolabo, France) and acetonitrile (Sigma-Aldrich Chemie GmbH, Germany). Boric acid, sodium hydroxide, phosphoric acid, potassium chloride, potassium dihydrogen phosphate and disodium hydrogen phosphate were all of spectroscopic grade. Phosphate buffer (0.1 M, pH 2-7), and borate buffer (0.1 M, pH 8-10) solutions were freshly prepared. Ultrapure water of 18 µΩ was obtained from a Millipore Milli-Q® UF Plus purification system (Millipore, Bedford, MA, USA). Human plasma was kindly provided by King Khaled University Hospital (King Saud University, Riyadh, KSA). After informed consent was obtained, fasting blood samples were taken and plasma was separated and stored at -70 °C.

Standard solutions

AZL stock solution (1 mg mL^{-1}) was prepared by dissolving accurately measured amounts of AZL reference standard material in methanol. This solution was found to be stable for several weeks when kept in the refrigerator. A working standard of $20 \text{ } \mu\text{g mL}^{-1}$ was prepared daily by dilution of stock standard solution with methanol.

Construction of the calibration graph

Aliquots of AZL standard solution were transferred into a series of 5 mL volumetric flasks to give final concentrations of $10 - 500 \text{ ng mL}^{-1}$. A volume of 0.9 mL of Cremophor RH40 (Cr RH 40) was added followed by addition of 1 mL of phosphate buffer and diluted to the mark with distilled water. The contents of the flasks were mixed well and the relative fluorescence intensity (RFI) was measured at 371 nm after excitation at 264 nm. RFI was plotted vs. nominal drug concentration (ng mL^{-1}) to obtain the calibration graph. The linear regression equation for the data was computed.

Assay of human plasma samples

Plasma samples were stored at $-20 \text{ }^{\circ}\text{C}$ and allowed to thaw at room temperature before processing. Twenty microliters of AZL standard solutions of different concentrations (3.2, 3.6, 4.8, 5.4, 6.0 $\mu\text{g/mL}$) were spiked into 200 μL of human plasma and mixed for 2 min. A volume of 100 μL of phosphate buffer pH 11 was added and the solution was vortexed for 1 minute, the volume was then completed to 1.5 mL with methanol and vortexed for other 2 min followed by centrifugation for 20 min at 12000 rpm at room temperature. The supernatant was then transferred and filtered through 0.2 μm syringe filter into glass vials and dried under a gentle stream of nitrogen. Finally, the residues were reconstituted in 50 μL methanol, 900 μL Cr RH 40 and 1 mL phosphate buffer (pH 3.0) and volume was completed to 3 mL with water. A blank plasma sample was treated similarly. RFI was measured at 371 nm after excitation at 264 nm and the concentration of the drug was calculated from the corresponding regression equation.

RESULTS

Figure 1 shows the chemical structure of AZL. The fluorescence properties of AZL in both aqueous and Cr RH 40 systems were studied where AZL exhibited an emission band at 371 nm after excitation at 264 nm. Figure 2 illustrates the fluorescence spectra of AZL in the two

systems. The first system was aqueous system, while the second was the same aqueous system in the presence of Cr RH 40 as a fluorescence enhancer. The optimum conditions for fluorimetric estimation of AZL were established through number of experiments.




Figure 1: Chemical structure of Azilsartan (AZL)




Figure 2: Excitation (1) and emission (2) spectra of AZL (200 ng mL^{-1}) in Cr RH 40 (1%, w/v); excitation (3) and emission (4) spectra of AZL (200 ng mL^{-1}) in water

Optimization of experimental conditions

Effect of organized media

The effect of different organized media on the RFI of AZL was studied by adding 0.5 mL, 1 % w/v solution of each surfactant to the drug solution. Different surfactants, like sodium dodecyl sulfate (SDS) [anionic surfactant], Cremophor EI, Cr RH 40, carboxymethylcellulose (CMC), tween 80 [nonionic surfactants] and macromolecules such as β -cyclodextrin were tried. The low critical micelle concentration (cmc) values of nonionic surfactants render them better solubilizers for hydrophobic drugs compared to ionic surfactants [30]. As shown in figure 3 three nonionic surfactants, namely Cr RH 40, Cr EL and Tween 20, demonstrated high RFI results for AZL determination.

Effect of volume of nonionic surfactants

The influence of Cr RH 40, Cr EL and Tween 20, on the RFI of AZL was studied using different volumes of 1 % w/v solutions. On increasing their volumes, Cr RH 40 showed the highest results (Fig 4). The RFI of AZL using Cr RH 40

increased significantly up to 800 μL (1 % w/v), where after this volume no more significant increase in RFI was observed. Therefore, 900 μL 1 % w/v Cr RH 40 solution was chosen for AZL determination.




Figure 3: Effect of different organized media (0.5 mL, 1 % w/v solution of each) on RFI of AZL (200 ng mL^{-1})




Figure 4: Effect of Cr RH 40, Cr EL and Tween 20 volumes (1 % w/v) on RFI of AZL (200 ng mL^{-1})




Figure 5: Effect of pH on the RFI of 400 ngmL⁻¹ AZL in 900 µL 1%, w/v Cr RH 40 solution in water (black column AZL with surfactant, gray column AZL without surfactant and white column surfactant only)

Effect of pH

The pH of micellar solutions can display significant influence on the degree of solubilization of some compounds, since it may alter the equilibrium between ionized and nonionized form of these compounds [30]. The effect of pH on RFI of AZL, Cr RH 40 and AZL-Cr RH 40 was examined utilizing different types of buffers covering the whole pH range, for instance 0.1 M phosphate buffer (cover pH range 2–7) and 0.1 M borate buffer (cover pH range 8–10). Results presented in Figure 5 showed that the optimum pH value for AZL determination with and without Cr RH 40 was 3.

Effect of diluting solvent

Dilution with various solvents such as water, methanol, ethanol and acetonitrile was employed. Water exhibited the highest RFI compared to the other studied solvents (Fig. 6), this may be due to changing the polarity of the medium which in turn may lead to physical interaction between the solvents and the drug molecules. Therefore, water was chosen as the diluting solvent throughout the study. A reduction in the RFI was detected in the micellar system using methanol, acetonitrile or ethanol. This may be attributed to the denaturation of the micelles by short-chain alcohols such as methanol and ethanol. Furthermore these alcohols may decrease the size of the micelles, and may breakdown the surfactant aggregate at high concentration [31].




Figure 6: Effect of the diluting solvent on fluorescence intensity of AZL (200 ngmL⁻¹); white column with surfactant and black column without surfactant

Effect of time

The influence of time on the stability of the RFI of AZL in micellar medium was also studied. It was found that the development of RFI was instantaneously and persisted stable for at least one hour.

Validation data

The proposed methods were validated according to the ICH-guidelines for validation of the analytical procedures [32] in terms of the

linearity, sensitivity, accuracy, specificity, repeatability and reproducibility

Linearity and range

The calibration graph for the determination of AZL by the proposed method was constructed by plotting the RFI versus the concentration. The graph was found to be rectilinear over the concentration range 10-500 ngmL⁻¹ (Table 1).

Statistical analysis [33] of the data gave high value of the correlation coefficient (r) of the regression equation, small values of; the standard deviation of residuals (Sy/x), intercept (Sa), slope (Sb), the percentage relative standard deviation and the percentage relative error (Table 1). These data proved the linearity of the calibration graph for the studied drug.

Table 1: Analytical performance data for the spectrofluorimetric determination of AZL

Parameter	AZL
Wavelength [λ_{ex} / λ_{em}] (nm)	264/371
Linearity range (ng/mL)	10 - 500
Intercept (a)	-33.07
Slope (b)	6.876
Correlation coefficient (r)	0.9984
S.D. of residuals (S _{y/x})	9.999
S.D. of intercept (S _a)	6.849
S.D. of slope (S _b)	0.0293
% RSD ^a	1.655
% Error ^b	0.7435
LOD (ngmL ⁻¹) ^c	3.287
LOQ (ngmL ⁻¹) ^d	9.961

^a Percentage relative standard deviation for three replicate samples; ^b Percentage relative error for three replicate samples; ^c Limit of detection; ^d Limit of quantitation

Limits of quantitation (LOQ) and of detection (LOD)

Limit of quantitation (LOQ) and limit of detection (LOD) were calculated in accordance with the ICH Q2 (R1) recommendation [32]. LOQ was determined by establishing the lowest concentration that can be measured below which the calibration graph is nonlinear. LOD was determined by evaluating the lowest concentration of the drug that can be detected. The results are also presented in Table 1. The values of LOQ and LOD were calculated according to the following equations:

$$\text{LOD} = 3.3 \sigma/S \quad (1)$$

$$\text{LOQ} = 10 \sigma/S \quad (2)$$

Where, σ was the standard deviation of the intercept of regression line and S was the slope of regression line of the calibration curve. The results are given in Table 1.

The reported data in the literature supported that our LOQ (9.961 ngmL⁻¹) is much lower than maximum plasma concentration (C_{max}) and hence can easily quantify AZL in plasma (reported C_{max} of AZL around 5.7 μgmL^{-1}) [34].

Accuracy and precision

Accuracy, intra-day and inter-day precisions of the proposed method were determined (anticipated in Tables 2 and 3). Three replicate samples in the same day, as well as on three consecutive days were analyzed for intra-day and inter-day precision at different concentrations. Accuracy was calculated as % bias using the following equation,

$$\text{Bias (\%)} = [(A-B) \times 100]/A \dots \dots \dots (3)$$

where A is nominal AZL concentration, and B the measured AZL concentration.

Bias ranged from -3.05 to 0.2 %, thus indicating the high accuracy of the method. The intra-day and inter-day precisions were expressed as recovery (% \pm RSD). The average recovery percentages (around 100 %) and the low relative standard deviations (RSD) indicated the inter-day and intra-day precisions of the method (Table 3).

Robustness

Robustness was assessed by testing the susceptibility of measurements to small changes of the analytical conditions. It was found that small differences that may take place during the experimental operation did not significantly change the response (RFI) of the current method. The results are abridged in Table 4.

Application of proposed method to analysis of AZL in human plasma

The high sensitivity of the proposed method allowed the determination of AZL in spiked human plasma. AZL is orally bioavailable, reaching peak plasma concentration after 3 of administration. The maximum plasma concentration (C_{max}) of AZL is around 5.7 μgmL^{-1} following oral dose of 80 mg [34]. Therefore vast dilutions were made to reach the dynamic linear range of the current method. Absolute recoveries of AZL in spiked human plasma samples were calculated from its corresponding regression equation. The results abridged in Table 5 reveal

that the % RSD and mean absolute recoveries of AZL in spiked plasma samples are 1.17 % and 90.54 %, respectively. The recovery values are better than those reported by Ramakrishna et al. [26] concerning LC with mass detection for

determination of AZL and chlorthalidone in human plasma. Relatively high plasma protein binding of AZL (>99 %) could be responsible for low recovery values (about 91 %).

Table 2: Accuracy of the spectrofluorimetric method for determination of AZL

Day	Actual conc. (ng/mL)	Mean conc. (ng/mL)	± SD	% Nominal	% RSD	% Bias	SEM
1	60	61.14	1.758	101.9	2.88	-1.88	0.72
2	60	60.39	2.457	100.65	4.07	-0.65	1.00
3	60	59.96	1.456	99.93	2.43	0.07	0.59
1	100	101.8	1.987	101.8	1.95	-1.78	0.81
2	100	101.9	4.964	101.9	4.87	-1.88	2.03
3	100	103.1	0.7685	103.1	0.75	-3.05	0.31
1	200	204.2	3.471	102.1	0.47	-2.08	1.42
2	200	200.3	0.9455	100.15	1.7	-0.15	0.39
3	200	199.6	3.036	99.8	1.52	0.2	1.24
1	400	399.7	3.469	99.93	1.3	0.08	1.42
2	400	407.6	4.662	101.9	1.14	-1.88	1.90
3	400	401.9	5.222	100.48	0.87	-0.47	2.13

SEM = standard error of the mean; 1, 2, 3 represents measurements obtained on day 1, day 2 and day 3 respectively (n = 3 for each day)

Table 3: Intra-assay and inter-assay precision and accuracy for determination of AZL by the proposed spectrofluorimetric method

Nominal conc. (ng/mL)	Intra-assay		Inter-assay	
	Measured conc. (ng/mL)	Recovery (% ± RSD) ^a	Measured conc. (ng/mL)	Recovery (% ± RSD) ^a
60	61.52	102.53±2.37	60.5	100.83±0.99
100	80.94	101.18±1.77	102.27	102.27±0.71
200	101.03	101.03±1.29	201.37	100.68±1.23
400	200.24	100.12±0.61	403.07	100.77±1.01

^a Mean of three determinations

Table 5: Results of the determination of AZL in pure form and plasma samples

Parameter	Pure form		Plasma sample		
	Amount taken (ngmL ⁻¹)	% Found	Amount added (ngmL ⁻¹)	Amount found (ngmL ⁻¹)	% Found
	60	102.53	112	99.69	89.01
	80	101.18	128	116.51	91.02
	100	101.03	144	130.12	90.36
	200	100.12	160	146.83	91.77
Mean		101.22			90.54
± SD		0.99			1.17

DISCUSSION

Azilsartan (AZL) possesses weak native fluorescence in aqueous medium. Hence, we intended to enhance this emission band, in order to develop a new and sensitive method for the analysis of AZL in plasma. It became known that adding a surfactant at a concentration greater than its critical micellar concentration to a given fluorophore solution increases the molar

absorptivity and/or the fluorescence quantum yield of the fluorophore in many circumstances [7,35]. This fact has been used to increase the performance of spectrofluorimetric methods of various analytes. The fluorescence behaviour of AZL in various micellar media was studied and there was an enhancement about 300 % of the RFI in the presence of Cr RH 40 system under the optimum above mentioned conditions.

Table 4: Robustness of the proposed spectrofluorimetric method

Variable	Recovery±SD ^a (%)
No variation^b	100.62 ± 0.18
Cr RH 40 volume (µL)	
870	99.27 ±2.11
930	102.74±.59
pH	
3.3	98.65±0.50
2.7	106.63 ±0.13
Buffer volume (µL)	
0.95	104.87± 0.39
1.05	103.43± 0.26
Temperature (°C)	
20	106.93 ± 0.08
30	93.17± 0.75

^a Mean of three determinations; ^b following the general calibration procedures

For exploring whether the enhancement of AZL fluorescence was due to rise in quantum yield or due to increment of absorbance of AZL at λ_{ex} ; the molar absorptivity of AZL in Cr RH 40 ($\epsilon_{micellar}$) was calculated at 264 nm (λ_{ex}). The $\epsilon_{micellar}/\epsilon_{acetonitrile}$ ratio was unity which indicated that the increase in sensitivity is not affected by an increase in the absorption of the drug in micellar system at its λ_{ex} . The increase in the quantum yield of AZL in Cr RH 40 was produced by protection of the lowest excited singlet state from non-radiative processes in the micellar system. The quantum yield of AZL was found to be 0.249 in methanol and 0.628 in the presence of Cr RH 40. The quantum yield was calculated according to the following equation [36]:

$$\Phi_d = \Phi_q (F_d/F_q) \cdot (A_q/A_d) \dots \dots \dots (4)$$

where Φ_d and Φ_q referred to the fluorescence quantum yields of AZL and quinine, respectively; F_d and F_q represent the integral fluorescence intensities of AZL and quinine, respectively; A_d and A_q referred to the values of absorbance of the drug and quinine at the excitation wavelength, respectively. The concentration was selected so that the absorbance was less than 0.05 to reduce the error arising from the inner effect [37].

CONCLUSION

A simple and sensitive spectrofluorimetric method was developed for the determination of AZL through enhancement of its native fluorescence. The suggested method is simple, less time consuming and does not require the

elaborate treatment associated with chromatographic methods; moreover, it is sensitive and no need for derivatization reaction. By virtue of its simplicity, rapidity and sensitivity, the proposed method can be applied for the analysis of the AZL in spiked human plasma.

ACKNOWLEDGEMENT

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at the King Saud University for funding this work through the Research Group Project no. RGP-322.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

CONTRIBUTION OF AUTHORS

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

REFERENCES

- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C. Heart disease and stroke statistics—2010 update A report from the American Heart Association. *Circulation* 2010; 121(7): e46-e215.
- Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. *J Clin Hypertens.* 2011; 13(2): 81-88.
- Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. *J Am Board Fam Med.* 2007; 20(1): 72-80.
- U.S. Food and Drug Administration (FDA). Azilsartan medoxomil. In: Center for drug evaluation and Research, editor. MD, USA; 25th February 2011.
- Kaur K, Saini SS, Malik AK, Singh B. Micelle enhanced and terbium sensitized spectrofluorimetric determination of danofloxacin in milk using molecularly imprinted solid phase extraction. *Spectrochim Acta A Mol Biomol Spectrosc.* 2012; 96: 790-795.
- Ocana JA, Barragan FJ, Callejon M. Spectrofluorimetric and micelle-enhanced spectrofluorimetric determination of gatifloxacin in human urine and serum. *J Pharm Biomed Anal.* 2005; 37(2): 327-332.
- Walash MI, Belal F, Tolba MM, Halawa MI. Micelle-enhanced spectrofluorimetric determination of

- amlexanox in bioadhesive buccal tablets: application to content uniformity testing. *Luminescence* 2015; 30(6): 823-829.
8. Alarfaj NA, El-Tohamy MF. Determination of the antiviral drug Ribavirin in dosage forms via micelle enhanced spectrofluorimetric method. *Luminescence* 2013; 28(2): 190-194.
 9. Ghasemi JB, Zolfonoun E. Application of principal component analysis–multivariate adaptive regression splines for the simultaneous spectrofluorimetric determination of dialkyltins in micellar media. *Spectrochim Acta A Mol Biomol Spectrosc.* 2013; 115: 357-363.
 10. Hanguo H, Xiaoxia G, Yan L, Sengtie L. Fluorometric Determination of Trace Amounts of Samarium and Europium in Geological Samples with Thenoyltrifluoroacetone–phenanthroline Tween 20 Micellar System. *Anal Lab.* 1987; 9: 6-11.
 11. Maggio RM, Piccirilli GN, Escandar GM. Fluorescence enhancement of carbendazim in the presence of cyclodextrins and micellar media: A reappraisal. *Appl Spectrosc.* 2005; 59(7): 873-880
 12. Nevado JB, Pulgarin JM, Laguna MG. Spectrofluorimetric study of the β -cyclodextrin: vitamin K 3 complex and determination of vitamin K 3. *Talanta* 2001; 53(5): 951-959.
 13. Christiansen A, Backensfeld T, Weitschies W. Effects of non-ionic surfactants on *in vitro* triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. *Eur J Pharm Sci.* 2010; 41(2): 376-382.
 14. Gandhi S, Mittal P, Pahade A, Rege S. Development and validation of stability indicating hptlc method for estimation of azilsartan medoximil. *Inter J Pharm Sci.* 2015; 6(1): 224-232.
 15. Srinivasan R, Chandra JK, Kumar DR, Kumar ND. Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form. *Int J Pharm anal res.* 2014; 3(4): 445-52.
 16. Mantena BP, Rao SV, Appa Rao KC, Ramakrishna K, Srikanth Reddy R. Method Development and Validation for the Determination of Potential Impurities Present in Azilsartan medoxomil Tablets by Reverse Phase-Ultra Performance Liquid Chromatography. *Anal Chem Lett.* 2014; 4(5-6): 287-301.
 17. Gorla R, Nagaraju C, Sreenivasulu B, Sreenivas N, Korupolu RB. New Simple UV Spectrophotometric Method for Determination of Azilsartan medoxomil in Bulk and Pharmaceutical dosage forms. *Int J Res Pharm Biomed Sci.* 2013; 4: 1133-1137.
 18. Gorla R, Sreenivasulu B, Garaga S, Sreenivas N. A simple and sensitive stability-indicating hptlc assay method for the determination of azilsartan medoxomil. *Indo Amer J Pharm Res.* 2014; 4(6): 2985-2992.
 19. Gong C, Wang J, Sun Y, Ding D, Zhong L, Zhu M, Sun J, Zhang X. UPLC–MS/MS for the determination of azilsartan in beagle dog plasma and its application in a pharmacokinetics study. *Asian J Pharm Sci.* 2015; 10(3): 247-253.
 20. Vekariya PP, Joshi HS. Development and validation of RP-HPLC method for azilsartan medoxomil potassium quantitation in human plasma by solid phase extraction procedure. *Int Sch Res Notices* 2013; 2013: 1-6.
 21. Ebeid WM, Elkady EF, El-Zaher AA, El-Bagary RI, Patonay G. Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and Chlorthalidone to Be Utilized in Their Determination in Pharmaceuticals. *Anal chem insights* 2014; 9: 33-40.
 22. Ebeid WM, Elkady EF, El-Zaher AA, El-Bagary RI, Patonay G. Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics. *Anal bioanal chem.* 2014; 406(26): 6701-6712.
 23. Kasimala MB, Kasimala BB. Reverse phase-HPLC method development and validation for the simultaneous estimation of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms. *J Atoms Mol.* 2012; 2(1): 117-126.
 24. Naazneen S, Sridevi A. Stability-indicating RP-HPLC method for the simultaneous estimation of azilsartan medoxomil and chlorthalidone in solid dosage forms. *Int J Pharm Pharm Sci.* 2014; 6(6): 226-243.
 25. Sravani P, Rubesh Kumar S, Duganath N, Devanna N. Method Development and Validation for the Simultaneous Estimation of Azilsartan and Chlorthalidone by RP-HPLC in Pharmaceutical Dosage Form. *Int J Pharm Sci.* 2014; 4(5): 725-729.
 26. Ramakrishna R, kumar Puttrevu S, Bhatia M, Bala V, Sharma VL, Bhatta RS. Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry. *J Chromatogr B* 2015; 990: 185-197.
 27. El-Enany NM, El-Sherbiny DT, Abdelal AA, Belal FF. Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde. *J Fluoresc.* 2010; 20(2): 463-472.
 28. Mandal B, Balabathula P, Mittal N, Wood GC, Bhattacharjee H. Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma. *J Fluoresc.* 2012; 22(6): 1425-1429.
 29. El-Sayed FAL, Mohamed TA, Taha AE. Spectrofluorimetric determination of carvedilol in dosage form and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride. *Chem. Ind. Chem. Eng. Q.* 2010; 16(1): 31-38.
 30. Rangel-Yagui CO, Pessoa Jr A, Tavares LC. Micellar solubilization of drugs. *J Pharm Pharm Sci.* 2005; 8(2): 147-163.
 31. Leung R, Shah DO. Dynamic properties of micellar solutions: I. Effects of short-chain alcohols and polymers on micellar stability. *J Colloid Interface Sci.* 1986; 113(2): 484-499.
 32. ICH. Validation of Analytical procedures. Methodology (Q2AR1), International Conference on Harmonization;

- November 1996 and November 2005; USA.: Food and Drug Administration; November 1996 and November 2005.
33. Miller JN, Miller JC. *Statistics and chemometrics for analytical chemistry*; Pearson Education; 2005.
 34. European Medicines Agency (EMA). *Azilsartan medoxomil, Edarbi Assesment report*. London, UK; 2011.
 35. Darwish HW, Abdelhameed AS, Bakheit AH, Alanazi AM. *A new method to determine the new C-Met inhibitor "Cabozantinib" in dosage form and human plasma via micelle-enhanced spectrofluorimetry*. *RSC Adv*. 2015; 5(51): 40484-40490.
 36. Tang B, Wang X, Jia B, Niu J, Wei Y, Chen Z, Wang Y. *Simple, rapid, and sensitive spectrofluorimetric determination of Zaleplon in micellar medium*. *Anal lett*. 2003; 36(14): 2985-2997.
 37. Lakowicz JR. *Principles of fluorescence spectroscopy*; Springer Science & Business Media; 2007.